Literature DB >> 24639866

Silent Myocardial Ischemia:A challenge for the doctors.

Zhoupeng Wu1, Jichun Zhao2.   

Abstract

Entities:  

Year:  2014        PMID: 24639866      PMCID: PMC3955577          DOI: 10.12669/pjms.301.4685

Source DB:  PubMed          Journal:  Pak J Med Sci        ISSN: 1681-715X            Impact factor:   1.088


× No keyword cloud information.
Silent myocardial ischemia (SMI) is an asymptomatic coronary syndrome without a history of infarction, and is associated with a higher risk of cardiovascular events.[1] SMI is usually detected incidentally during routine controls. Although there is a high prevalence in elderly female patients, routine screening is not recommended1.As in this current case, in patients with SMI, in addition to aspirin, statin, and angiotensin receptor blockers, beta blocker therapy should be considered in the treatment.[2] The routine use of proton pump inhibitors is not recommended in patients taking daily doses of aspirin.[2] The contemporary incidence of left ventricular (LV) thrombus after acute MI is approximately 5 %, and systemic embolization in patients with LV thrombus is mostly associated with decreased LV ejection fraction and LV aneurysm.[3] Most episodes of systemic embolization occur in the first two weeks after acute MI[3]. In patients with multiple systemic embolic infarctions, further investigation including cardiac evaluation with transthoracic echocardiography (TTE) as an initial diagnostic test should be carried out to detect an embolic origin.[4] Transesophageal echocardiography (TEE) is suggested to perform in clinical conditions when there is a question about the information obtained using TTE. TEE is especially recommended in identification of cardioembolic source, assessment of left atrial appendage, and intra cardiac masses.[5] Anticoagulation with warfarin sodium should be prescribed to patients found to have an LV thrombus or embolic phenomenon. Prophylactic anticoagulation could be considered even in patients with LV dysfunction and extensive wall motion abnormalities that do not have a thrombus.[4] Actually, about the necessity of TEE and anticoagulant therapy in patients with cryptogenic MI, in this current case, there was no clear evidence about the association between multiple systemic embolization and MI. In conclusion, in patients with systemic embolization, there is no doubt that TEE should be performed even in clinical suspicion of cardio embolic source, and anticoagulant therapy should be considered as an acceptable option for initial therapy whatever the cause is.
  4 in total

Review 1.  Expert consensus document on the use of antiplatelet agents. The task force on the use of antiplatelet agents in patients with atherosclerotic cardiovascular disease of the European society of cardiology.

Authors:  Carlo Patrono; Fedor Bachmann; Colin Baigent; Christopher Bode; Raffaele De Caterina; Bernard Charbonnier; Desmond Fitzgerald; Jack Hirsh; Steen Husted; Jan Kvasnicka; Gilles Montalescot; Luis Alberto García Rodríguez; Freek Verheugt; Jozef Vermylen; Lars Wallentin; Silvia G Priori; Maria Angeles Alonso Garcia; Jean Jacques Blanc; Andrzej Budaj; Martin Cowie; Veronica Dean; Jaap Deckers; Enrique Fernández Burgos; John Lekakis; Bertil Lindahl; Gianfranco Mazzotta; João Morais; Ali Oto; Otto A Smiseth; João Morais; Jaap Deckers; Rafael Ferreira; Gianfranco Mazzotta; Philippe Gabriel Steg; Frederico Teixeira; Robert Wilcox
Journal:  Eur Heart J       Date:  2004-01       Impact factor: 29.983

Review 2.  2007 focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.

Authors:  Elliott M Antman; Mary Hand; Paul W Armstrong; Eric R Bates; Lee A Green; Lakshmi K Halasyamani; Judith S Hochman; Harlan M Krumholz; Gervasio A Lamas; Charles J Mullany; David L Pearle; Michael A Sloan; Sidney C Smith; Daniel T Anbe; Frederick G Kushner; Joseph P Ornato; David L Pearle; Michael A Sloan; Alice K Jacobs; Cynthia D Adams; Jeffrey L Anderson; Christopher E Buller; Mark A Creager; Steven M Ettinger; Jonathan L Halperin; Sharon A Hunt; Bruce W Lytle; Rick Nishimura; Richard L Page; Barbara Riegel; Lynn G Tarkington; Clyde W Yancy
Journal:  J Am Coll Cardiol       Date:  2008-01-15       Impact factor: 24.094

3.  The early presentation of atrial myxoma with acute myocardial infarction.

Authors:  Mohammad-Hassan Namazee; Hamid-Reza Rohani-Sarvestani; Ali-Reza Serati
Journal:  Arch Iran Med       Date:  2008-01       Impact factor: 1.354

4.  Effects of anti-ischaemic drug therapy in silent myocardial ischaemia type I: the Swiss Interventional Study on Silent Ischaemia type I (SWISSI I): a randomized, controlled pilot study.

Authors:  Paul Erne; Andreas W Schoenenberger; Michel Zuber; Dieter Burckhardt; Wolfgang Kiowski; Paul Dubach; Therese Resink; Matthias Pfisterer
Journal:  Eur Heart J       Date:  2007-07-19       Impact factor: 29.983

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.